At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 80 enrolled
Drug / intervention
carboxymethylcellulose 0.5%/glycerin 0.9% +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye
In Brief
A Phase 4 clinical trial evaluating carboxymethylcellulose 0.5%/glycerin 0.9% and sodium hyaluronate 0.18% for Dry Eye Syndromes and Keratoconjunctivitis Sicca. Completed, enrolled 80 participants across 2 sites in 2 countries.
Detailed Summary
This study will evaluate the safety and efficacy of OPTIVE FUSION™ compared to VISMED® Multi for the management of dry eye.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye Syndromes, Keratoconjunctivitis Sicca
CountriesFrance, United Kingdom
Collaborators--
Timeline
Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedApr 2014
Enrollment StartMay 2014
Primary CompletionJan 2015
Study CompletionMar 2015
TodayJul 2026
First PostedApr 21, 2014
Enrollment StartMay 14, 2014
Primary CompletionJan 27, 2015
Study CompletionMar 17, 2015
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 12.2 years ago
Interventions
carboxymethylcellulose 0.5%/glycerin 0.9%drug
1-2 drops OPTIVE FUSION™ (carboxymethylcellulose 0.5%/glycerin 0.9%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.
sodium hyaluronate 0.18%drug
1-2 drops VISMED® Multi (sodium hyaluronate 0.18%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.